Neflamapimod
Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
EIP Pharma IncSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Nonfluent Variant Primary Progressive Aphasia (nfvPPA) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLORTAUCIPIR Mayo Clinic | Phase 4 | BB |
LEVODOPA Shirley Ryan AbilityLab | Phase 2/3 | B |
carbidopa Shirley Ryan AbilityLab | Phase 2/3 | B |
PITTSBURGH COMPOUND B UNLABELLED Mayo Clinic | Phase 1 | CC |
FLUDEOXYGLUCOSE Mayo Clinic | Phase 1 | CC |
Aadvac1 Axon Neuroscience SE | Phase 1 | CC |
GOSURANEMAB University of California, San Francisco | Phase 1 | CC |
Same molecule, other indications
Neflamapimod is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →